

2019



NPO Petrovax Pharm

02

NPO Petrovax Pharm



A Russian full-cycle biopharmaceutical company with a 20-year record of success on the pharma market

An **Interros Group** company



R&D Center

> 20 worldwide patents



Pharmaceutical exports to the EAEU, EU, and Iran. Localization of vaccines in Belarus and Iran

The company is among the **Top-5** immunobiological manufacturers in Russia

A **partner** of leading global pharmaceutical companies



A **full-cycle** biopharmaceutical company
GMP and ISO-compliant **manufacturing facilities**



A **portfolio of original** immunobiological products and vaccines

650 highly skilled employees



03

Grippol® plus

(Influenza vaccine [inactivated] + Azoximer bromide)

A Russian trivalent inactivated influenza vaccine, preservative-free, in pre-filled syringes



Grippol® Quadrivalent

(Influenza vaccine [inactivated] + Azoximer bromide)

The first Russian quadrivalent inactivated subunit influenza vaccine to protect against 4 flu virus strains, i.e. 2 virus A strains (A/H1N1 + A/H3N2), and 2 lineages of influenza B virus (B/Yamagata + B/Victoria). It is preservative-free, and supplied in pre-filled syringes.



ORIGINAL PRODUCT PORTFOLIO

An advanced combined-effect enzyme for the treatment of connective tissue hyperplasia conditions

Longidaze®

(Bovhyaluronidase azoximer)



Polyoxidonium®

(Azoximer bromide)

A multi-purpose pharmaceutical product with immunomodulating, detoxifying, and antioxidative properties.

The product is indicated for the treatment and prevention of respiratory infections as well as for the treatment efficacy improvement in gynecology and urology.



Imoferaza®

A specialized external scar revision cream for the care of scars and cicatricial tissue; it contains immobilized hyaluronidase, an unique enzyme.



04

A vaccine for prevention of pneumococcal infections caused by *Streptococcus pneumoniae*, serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F, such as sepsis, bacteremia, meningitis, pneumonia, and acute otitis media.

Indicated for subjects aged 2+ months without further age restrictions.

The finished dosage form is manufactured as a full-cycle process by NPO Petrovax Pharm in cooperation with Pfizer.

Prevenar® 13

(13-valent polysaccharide adsorbed pneumococcal vaccine)



INTERNATIONAL PROJECTS LOCALIZED PHARMACEUTICALS

An innovative thrombolytic agent for the treatment of myocardial infarction. The only recommended single-injection, bolus-dose (for 5-10 seconds) thrombolytic agent in the world to be used in the emergency care setting in patients with acute myocardial infarction to provide medical aid within the shortest time possible.

Currently, tenecteplase is one of the most thoroughly studied thrombolytics worldwide.

Manufacturer: NPO Petrovax Pharm in cooperation with Boehringer Ingelheim.



Actilyse®


(Alteplase)



A biotechnology thrombolytic agent to treat both myocardial infarction and ischemic stroke (which is major advantage and a unique evidence-based indication).

Alteplase is the only thrombolytic medication indicated in patients with ischemic stroke within 4.5 hours following the onset of the symptoms.

Manufacturer: NPO Petrovax Pharm in cooperation with Boehringer Ingelheim.



Metalyse®

(Tenecteplase)



R&D Efforts

An in-house R&D Center: the development of **innovative pharmaceuticals** and new dosage forms from **molecule synthesis** to pharmaceutical product authorization

The company holds **20 worldwide patents** for molecules, inventions, technologies, and pharmaceutical products

R&D projects

In the pipeline:
a conjugate
platform-based
antiviral agent



Results of 2017-2018



Polyoxidonium®

- A Post-Authorization Safety Study (PASS) for Polyoxidonium® has been successfully completed in Slovakia.
- Polyoxidonium® tablets label has been extended to include children aged 3+ years, pursuant to the Russian Ministry's of Health Guideline of June 01, 2017.



Grippol® Quadrivalent

The first in Russia quadrivalent influenza vaccine; launched to the market in 2018.



06


R&D Results

Petrovax Pharm's development concept is based on branded products. The R&D and Implementation Department structure provides for the molecule inception and the product lifecycle support from the idea to practical implementation. Ad hoc research involves leading local and foreign industry-specific scientific institutions.




In-house vivarium

Petrovax Pharm has an in-house vivarium for a wide range of preclinical efficacy and safety studies in mice, rats, rabbits, and guinea pigs. Specific temperature, air humidity, and light conditions are maintained in the animal facility rooms, which provides for keeping SPF mice and rats as well as conventional rabbits and guinea pigs. Preclinical data from in-house studies make the foundation for marketing authorization applications for the products developed by Petrovax Pharm. The company's R&D units have been issued ISO:9001 quality certificates. Contract research orders are welcome.



An advanced search for promising candidate molecules with further preclinical evaluation of safety and potency.

Mechanism-of-action studies in the disease pathogenesis setting for the products under development.



Preclinical safety and efficacy studies for medicinal products-to-be.

The development of quality control techniques and production process.



Planning and management of GCP-compliant authorization clinical trials. Implementation of innovative technologies; optimization of state-of-the-art processes; production scale-up.

Production



Petrovax Pharm is a full-cycle pharmaceutical company. Manufacturing facilities are fully compliant with the applicable Russian and international GMP standards and ISO 9001:2015 (cleanliness class zoning, raw and other material, personnel, intermediate and finished product flows).



The company's state-of-the-art pharmaceutical manufacturing and warehousing complex was put in operation in Moscow Region in 2008 and is among Russia's most advanced high-tech biopharmaceutical facilities. NPO Petrovax Pharm is the only immunobiological manufacturer in Russia holding international GMP certificates issued by the state regulatory authorities of the EU (Slovakia) and Iran.



The company manufactures active pharmaceutical ingredients (APIs) and liquid, semi-solid, and solid dosage forms in pre-filled syringes, ampoules, vials, and polymer containers. Its production capacities provide for releasing over 160 million shots of immunobiologicals a year.



1st production line: pre-filled syringe products
2nd production line: injectables in ampoules and vials
3rd production line: APIs, semi-solid, and solid dosage forms

Quality



Petrovax Pharm has an effective quality management system (QMS) in place, with an ISO 9001:2015 certificate issued.

Importantly, QMS covers not only the production unit but also all other units, including the R&D unit and the company's office.



- The QMS high-level performance is annually certified through a comprehensive audit by ISO certification authorities.
- The document workflow system provides for keeping track of all actions by the employees engaged in product manufacturing and quality control, both in real time and historically.



- The company cooperates with approved raw and other material suppliers only.
- The company has an automated training system in place: WebTutor, an education and professional development web portal, provides each employee with an individual QMS training and testing plan.



A pharmacovigilance system is in place at the company that is run in compliance with the applicable international and Russian regulatory guidelines. To provide for product safety control, the company's pharmacovigilance responsible persons continuously monitor the relevant product efficacy and adverse event data.

09

Geography

Petrovax Pharm's strategic goals include the expansion of export potential and geographic footprint in respect of sales.

The company operates in all Russian regions and exports its pharmaceutical products to 11 countries.

There are plans of expanding the company's presence in these countries, including the EU, as well as entering South American markets.



> 30 Russia's largest cities

> 10 Export countries



Belarus: in 2015, the first in the Russian history manufacturing localization project was implemented that involved the Russian branded Grippol® plus influenza vaccine to be produced in Belarus under the agreement with the Belorussian Ministry of Health and the Republican Unitary Enterprise 'Belmedpreparaty'.



Iran: a strategic cooperation aimed to localize production of Grippol® plus influenza vaccine in Iran as well as transfer the relevant 4-valent polymer subunit influenza vaccine production technologies.

10

International Projects

Petrovax Pharm

Petrovax Pharm collaborates with leading Russian and international research institutes and pharmaceutical companies to develop new products and transfer full-cycle pharmaceutical manufacturing technologies.



A biotechnological project unique to the Russian scientific and production areas

- GMP-compliant facility construction.
- Personnel training and implementation of GMP-compliant sterile vaccine manufacturing standards.
- Production of the first Russian Grippol® plus mercury preservative-free vaccine in pre-filled syringes. Since 2009, the vaccine has been procured for the National Immunization Schedule.
- More than 120 million people were immunized with Grippol® plus over the entire successful vaccination period, including under the Russian National Immunization Schedule as well as in the EAEU and Iran .



Localization of immunobiological products in Russia with a transfer of innovative full-cycle production technologies

- Localization of Prevenar® 13, a 13-valent conjugate pneumococcal vaccine, in Russia including a full-cycle production, control and quality assurance technology in compliance with the applicable international GMP standards.
- Since 2014, the pneumococcal vaccine has been supplied under the Russian National Immunization Schedule. In 5 years, 18 million vaccine shots were supplied .
- Production potential for foreign markets.



Localization of full-cycle production of cardiac pharmaceuticals

- NPO Petrovax Pharm is the second site in the world manufacturing Boehringer Ingelheim's innovative thrombolytic agents.
- The production capacities provide for fully meeting the relevant patient demand in Russia.
- 2017: first commercial batches produced.
- 2019: a full-cycle manufacturing process to be implemented.

11

Company's growth dynamics: 2013 → 2018



In 2014–2017, an average growth rate in terms of annual revenues and net profits was **155%** and **34%**, respectively. Exports accounted for 11.2 % of the company's total sales as of 2017.



R&D. Market launch of Imoferaza®. Development of Grippol® Quadrivalent, a 4-valent influenza vaccine. Implementation of Polyoxidonium® and Imoferaza® new pharmaceutical forms related projects.



International partnerships

Successful implementation of a joint project with Pfizer and a start of a new project with Boehringer Ingelheim.



An updated marketing strategy

Launch of a media campaign and online promotion.



Production upgrade

Start and completion of the 3rd production line construction. GMP certificates issued by the Russian Federation, EU, Iran, Belarus. The 'Labelling' project.



An efficient regional team

More than 70 employees in 30 cities.
CRM implementation.



Export footprint expansion to the EAEU, EU, and Iran. Transfer of Grippol® Plus production technologies to Belarus .



Business solution automation

Process optimization and management performance boost.

Awards



In 2012, Pfizer and NPO Petrovax Pharm's pneumococcal vaccine localization project won the All-Russian Contest «**Platinum Ounce - 2011**» in the category "Project of the year".



NPO Petrovax Pharm won the All-Russia Contest of the **Russian Union of Industrialists and Entrepreneurs (RUIE) 'Russian Business Leaders: Performance and Commitment' 2017'** in the category 'For the Dynamic Development of Business'



In 2018, NPO Petrovax Pharm won the **National Import Substitution Award 'PRIORITY-2018'** for Grippol® Quadrivalent vaccine



Polyoxidonium® won the Russian Pharma Awards in the category 'The Medication of Choice for ARVI and influenza prevention in children' in 2016–2018 and the SmartPharma® Awards in 2018

Longidaze® won the Russian Pharma Awards in the category 'The Medication of Choice for pathogenetic treatment of chronic prostatitis and relapse prevention' in 2018



**Thank you for
your attention!**

NPO Petrovax Pharma LLC
1 Sosnovaya St., Pokrov Village, Podolsk,
Moscow region, 142143 Russia
Tel. : +7 (495) 730-75-45
E-mail: info@petrovax.ru
www.petrovax.ru